Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for ...
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead ...
BE Semiconductor Industries N.V. €130.40-5.60-4.12% ...
Bonus May 31, 2018 Jun 02, 2018 Apr 19, 2018 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Jun 16, 2009 Jun 17, 2009 Apr 20, 2009 Bonus Ratio: 1 share(s) for every 1 shares held Bonus Jul 28, ...
6 share for every 109 held at a price of Rs 271.0 Splits Sep 12, 2011 Sep 13, 2011 May 26, 2011 Split: Old FV10.0| New FV:2.0 Rights Sep 09, 2008 Sep 16, 2008 May 29, 2008 Rights ratio: 1 share for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results